3SBIO

1530
14.0902.42% ( -0.350 )
Delay Closed: Nov 16, 16:08:11

Overview

3SBIO (1530)

3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of...

Open
13.700
High
14.440
Low
13.520
Prev. Close
14.440
Volume
19.29M
Turnover
269.60M
Avg Price
13.973
Bid/Ask Ratio
-97.46%
Amplitude
6.37%
52wk High
35.170
Volume Ratio
0.48
Turnover Ratio
0.77%
52wk Low
13.050
HK Mkt Cap
35.42B
Market CapHKD
35.42B
P/ETTM
3.72
P/EDynamic
13.42
P/EStatic
--
EPSTTM
3.79
EPSDynamic
1.05
EPSStatic
--
BVPS
12.60
P/B
1.12
HK Shares
2.51B
Dividend YieldTTM
1.79%
DividendTTM
0.252
Shares
2.51B
Min lot size
500
Currency
HKD

3SBIO Analyst Rating

View more

Forecast & Rating

Nov 11, 2026
Price forecast
HK$28.94105.39%
Forecast & RatingStrong buy
14analysts
  • Strong buy64.29%
  • Buy28.57%
  • Hold7.14%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    3SBio opened 5.1% lower but clawed back to close at HK$14.19, down 1.73%, after touching HK$13.56 at 09:31 BJ and rebounding to HK$14.26 at 13:04 BJ on HK$258 million turnover; a fresh 5% slide during Hong Kong hours and proposed US curbs on Chinese biotech investment kept sentiment on the sector subdued. Fundamentals cut against the tape: Q2 2026 revenue rose 9.54% year on year to HK$2.61 billion and operating profit gained 29.88% to HK$891 million, yet net profit fell 11.01% to HK$662 million and EPS slipped 16.56% to HK$0.256. The shares trade below the MA20 of HK$14.32 and MA60 of HK$15.47, down 42.27% year to date, 59.94% below the 52-week high of HK$35.42 and only 8.74% above the HK$13.05 low, on a 3.75x PE. UBS and Citic Securities have nonetheless kept Buy ratings.

  2. Nov, 5

    3SBio rose 4.41% to HK$15.40 from HK$14.75, staging a high-open rebound after an early dip as UBS reaffirmed its rating and Guosheng Securities highlighted China's improving pharmaceutical innovation efficiency, lifting sentiment across Hong Kong innovative-drug names. The stock opened at HK$15.00, dipped to HK$14.80, reached HK$15.56 at 09:52 in the morning session, then consolidated between HK$15.13 and HK$15.50 in the afternoon on HK$391m turnover. Q2 2026 revenue rose 9.54% YoY to HK$2.61bn and operating profit jumped 29.88% to HK$891m, but net profit fell 11.01% to HK$662m and EPS slipped 16.56% to HK$0.256, showing revenue growth without profit growth. At HK$15.40, the shares remain below the 60-day MA of HK$15.75, 56.52% below the 52-week high of HK$35.42 and down 37.35% YTD, though 18.01% above the 52-week low of HK$13.05 and above the 20-day MA of HK$14.26. Still, proposed US restrictions on Chinese biotech investment continue to weigh on sector sentiment.

  3. Nov, 4

    3SBio staged a low-open, high-close session, finishing up 5.9% at HK$14.75 on 26.88 million shares worth HK$385.9 million, as renewed appetite for innovative-drug names and UBS's reiterated Buy rating carried the stock from a 13.92 morning trough to 14.78 at 15:10. The move sits against mixed fundamentals: Q2 2026 revenue rose 9.54% year on year to HK$2.61 billion and operating income jumped 29.88% to HK$891 million, yet net profit fell 11.01% to HK$662 million and EPS slipped 16.56% to HK$0.256. Price is above the 14.28 MA20 but below the 15.79 MA60, down 39.99% year to date, 58.36% below the 35.42 52-week high and just 13.03% above the 13.05 low of 26 October, with a 3.89x PE. Proposed US curbs on biotech investment in China remain unresolved, though.

  4. Oct, 27

    News that the US plans to curb investment in Chinese biotech weighed on the sector, sending 3SBio 4.8% lower to HK$13.24 after opening at HK$13.91 and sliding through the session; turnover reached 24.77 million shares worth about HK$330 million, with the intraday low of HK$13.05 near the 52-week low set the previous day. Fundamentals cut against the price action: Q2 revenue rose 9.54% yoy to HK$2.61 billion and operating income climbed 29.88% to HK$891 million, yet net profit fell 11.01% to HK$662 million and EPS slipped 16.56% to HK$0.256, with PE around 3.49x and PB around 1.05x. The stock is down 46.14% year-to-date, 62.62% below its 52-week high of HK$35.42, and trades under its MA20 of HK$14.887. One analyst initiated coverage with a HK$17.8 target price, and the company repurchased 337,500 shares on 14 October; though peers weakened in tandem, suggesting sector-wide rather than company-specific pressure.

  5. Oct, 22

    Dragged by a broadly weaker Hong Kong biotech sector, 3SBio opened at HK$14.33 on 22 October and slid through the session to close down 4.41% at HK$13.66, with the HK$13.46 touched at 13:52 BJ marking a fresh 52-week low on about HK$347 million turnover and a 1.01% turnover rate. The stock trades below its MA20 of HK$15.29 and MA60 of HK$16.30, down 44.43% year to date and 61.43% below its November 2025 high of HK$35.42. Fundamentals read differently from the tape: Q2 2026 revenue rose 9.54% year on year to HK$2.61 billion and operating income climbed 29.88% to HK$891 million, yet net profit fell 11.01% to HK$662 million. The company repurchased roughly 2.14 million shares across 12 to 14 October, and one brokerage initiated coverage with a HK$17.8 target price. At PE 3.61x and PB 1.08x, though, net profit has now declined for two consecutive quarters, with revenue growth yet to reach the bottom line.

News

Bullish vs. Bearish — Last 3 Months

11.2k followers · 1 opinions
100%Bearish▼